Claiming A Range, Watch Out For The Presumption Of Obviousness
Disclosure of a broad prior-art dose range does not automatically render narrower claimed dosing regimens obvious without a demonstrated reason to select the claimed doses.
CAFC Upholds Win for Janssen on Patent for Antipsychotic Med Dosing Regimen
The U.S. Court of Appeals for the Federal Circuit affirmed that Teva Pharmaceuticals did not prove the claims of Janssen Pharmaceuticals' patent for antipsychotic dosing regimens invalid for obviousness.